Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients

Transplantation

Volumn 82, Issue 1, 2006, Pages 30-35

  Díaz Pedroche, Carmen ^a   Lumbreras, Carlos ^a   San Juan, Rafael ^a   Folgueira, Dolores ^a   Andrés, Amado ^a   Delgado, Juan ^a   Meneu, Juan Carlos ^a   Morales, José María ^a   Moreno Elola, Almudena ^a   Hernando, Susana ^a   Moreno González, Enrique ^a   Aguado, José María ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Cytomegalovirus; Prevention; Transplantation; Valganciclovir

Indexed keywords

MYCOPHENOLIC ACID; STEROID; TACROLIMUS; VALGANCICLOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; GANCICLOVIR; VIRUS ANTIGEN;

ADULT; AGED; ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEART TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; THROMBOCYTOPENIA; VIRUS LOAD; VIRUS REPLICATION; ADOLESCENT; BLOOD; CHILD; CYTOMEGALIC INCLUSION BODY DISEASE; IMMUNOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION;

EID: 33747460001     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000225830.76907.d0     Document Type: Article

References (36)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741.
2. Jenkins FJ, Rowe DT, Rinaldo CR, Jr. Herpesvirus infections in organ transplant recipients. Clin Diagn Lab Immunol 2003; 10: 1.
3. Snydman DR. Infection in solid organ transplantation. Transpl Infect Dis 1999; 1: 21.
4. Falagas ME, Arbo M, Ruthazer R, et al. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation 1997; 63: 1595.
5. Falagas ME, Paya C, Ruthazer R, et al. Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. Transplantation 1998; 66: 1020.
6. George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc Gaithersburg, Maryland. Am J Med 1997; 103: 106.
7. Slifkin M, Doron S, Snydman DR. Viral prophylaxis in organ transplant patients. Drugs 2004; 64: 2763.
8. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995; 346: 69.
9. Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 1997; 350: 1729.
10. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001; 32: 742.
11. Hart GD, Paya CV. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 73.
12. Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 83.
13. Cocohoba JM, McNicholl IR. Valganciclovir: an advance in cytomegalovirus therapeutics. Ann Pharmacother 2002; 36: 1075.
14. Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005; 79: 1477.
15. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
16. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094.
17. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 2005; 40: 704.
18. Snydman DR. Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: the case for prophylaxis. Clin Infect Dis 2005; 40: 709.
19. Lumbreras C, Otero JR, Herrero JA, et al. Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies. Antimicrob Agents Chemother 1993; 37: 2490.
20. Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185: 854.
21. Couchoud C. Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation. Cochrane Database Syst Rev 2000; (2): CD001320.
22. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002; 35: 866.
23. Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78: 1390.
24. Grossi P, Kusne S, Rinaldo C, et al. Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors. Transplantation 1996; 61: 1659.
25. Zamora MR, Davis RD, Leonard C. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 2005; 80: 157.
26. Singh N, Wannstedt C, Keyes L, et al. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005; 79: 85.
27. Singh N, Wannstedt C, Keyes L, et al. Who among cytomegalovirus- seropositive liver transplant recipients is at risk for cytomegalovirus infection? Liver Transpl 2005; 11: 700.
28. Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032.
29. Singh N, Dummer JS, Kusne S, et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988; 158: 124.
30. Devyatko E, Zuckermann A, Ruzicka M, et al. Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation. J Heart Lung Transplant 2004; 23: 1277.
31. Babel N, Gabdrakhmanova L, Juergensen JS, et al. Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience. Transplantation 2004; 78: 283.
32. Lopez-Medrano F, Lumbreras C, Otero JR, et al. [Efficacy of preemptive therapy with ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients]. Med Clin (Barc) 2004; 122: 41.
33. Kusne S, Grossi P, Irish W, et al. Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1999; 68: 1125.
34. Reusser P, Cathomas G, Attenhofer R, et al. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 1999; 180: 247.
35. Steininger C, Kundi M, Kletzmayr J, et al. Antibody maturation and viremia after primary cytomegalovirus infection, in immunocompetent patients and kidney-transplant patients. J Infect Dis 2004; 190: 1908.
36. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346: 1119.